Chemistry:NJK14047
From HandWiki
NJK14047 is a drug which acts as a selective inhibitor of the enzyme p38 mitogen-activated protein kinase (p38 MAPK). It has antiviral and antiinflammatory effects and was originally developed as a potential treatment for inflammatory lung conditions such as influenza. Subsequent research has also shown promise for various other conditions in which inflammation plays a role, including Alzheimer's disease, asthma, arthritis and psoriasis.[1][2][3][4]
See also
References
- ↑ "A novel p38 mitogen activated protein kinase (MAPK) specific inhibitor suppresses respiratory syncytial virus and influenza A virus replication by inhibiting virus-induced p38 MAPK activation". Biochemical and Biophysical Research Communications 477 (3): 311–316. August 2016. doi:10.1016/j.bbrc.2016.06.111. PMID 27346133.
- ↑ "A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse". Alzheimer's Research & Therapy 12 (1): 45. April 2020. doi:10.1186/s13195-020-00617-2. PMID 32317025.
- ↑ "NJK14047 Suppression of the p38 MAPK Ameliorates OVA-Induced Allergic Asthma during Sensitization and Challenge Periods". Biomolecules & Therapeutics 31 (2): 183–192. March 2023. doi:10.4062/biomolther.2022.078. PMID 36171179.
- ↑ "NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation". International Immunopharmacology 130. March 2024. doi:10.1016/j.intimp.2024.111800. PMID 38447416.
 |  |
